LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Inicio・Lista de Acciones・Cogent Biosciences Inc

Cogent Biosciences Inc

Cerrado

36.27 -1.23

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

36.17

Máximo

36.77

Métricas clave
By Trading Economics
Ingresos	-7.4M -81M
BPA	-0.5
Empleados	205
EBITDA	-6.8M -79M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+42.35% upside

Dividendos
By Dow Jones
Próximas Ganancias	24 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	3.7B 5.8B
Apertura anterior	37.5
Cierre anterior	36.27

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

4.88 / 5.87 Soporte y Resistencia

Cogent Biosciences Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 feb 2026, 16:32 UTC

Ganancias

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

14 feb 2026, 22:02 UTC

Ganancias

Looking for Dividends? Consider Europe. -- Barrons.com

14 feb 2026, 09:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

13 feb 2026, 21:57 UTC

Ganancias

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

13 feb 2026, 21:20 UTC

Ganancias

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13 feb 2026, 21:05 UTC

Adquisiciones, fusiones, absorciones

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13 feb 2026, 20:45 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 feb 2026, 20:45 UTC

Charlas de Mercado

Dollar Pares Down Early Losses -- Market Talk

13 feb 2026, 20:39 UTC

Charlas de Mercado

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13 feb 2026, 20:28 UTC

Charlas de Mercado

Oil Settles Week Lower -- Market Talk

13 feb 2026, 19:51 UTC

Ganancias

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 feb 2026, 19:32 UTC

Charlas de Mercado

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 feb 2026, 19:32 UTC

Charlas de Mercado

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 feb 2026, 19:29 UTC

Ganancias

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13 feb 2026, 18:18 UTC

Adquisiciones, fusiones, absorciones

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13 feb 2026, 17:52 UTC

Ganancias

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13 feb 2026, 17:16 UTC

Ganancias

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 feb 2026, 17:10 UTC

Adquisiciones, fusiones, absorciones

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13 feb 2026, 16:59 UTC

Ganancias

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13 feb 2026, 16:39 UTC

Adquisiciones, fusiones, absorciones

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13 feb 2026, 16:11 UTC

Ganancias

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13 feb 2026, 16:07 UTC

Charlas de Mercado

Hungarian Forint Could Rise Further -- Market Talk

13 feb 2026, 15:54 UTC

Ganancias

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13 feb 2026, 15:26 UTC

Charlas de Mercado

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13 feb 2026, 15:01 UTC

Ganancias

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13 feb 2026, 15:00 UTC

Ganancias

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13 feb 2026, 14:50 UTC

Charlas de Mercado

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13 feb 2026, 14:44 UTC

Ganancias

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13 feb 2026, 14:22 UTC

Charlas de Mercado

Ganancias

Global Energy Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Cogent Biosciences Inc previsión

Precio Objetivo

By TipRanks

42.35% repunte

Estimación a 12 Meses

Media 52 USD 42.35%

Máximo 67 USD

Mínimo 39 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Cogent Biosciences Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Cogent Biosciences Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

4.88 / 5.87Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.